Connection Vol. 15: HER2 in Gastric Cancer
Gastric cancer is the fourth most commonly diagnosed cancer. Recently, Trastuzumab® has been shown to improve the survival of patients with advanced gastric cancer. Dako also received approval from the U.S. FDA to expand the intended use for HercepTest™ and HER2 FISH pharmDx™ Kit to include patients with metastatic gastric or gastroesophageal junction adenocarcinoma. This issue of Connection is especially dedicated to inform and update both the practitioners and observers about the the emerging use of Trastuzumab® in gastric cancer, pharmacodiagnostics, and the salient differences between breast and gastric cancer HER2 testing.
Download the full Connection Vol. 15
Literature Order No. 28830